Boiron: Net Income Up 188%, But Base Effect Needs Contextualization
Boiron Laboratories will release its 2025 results on Thursday, showing a significant increase in profitability, with net income rising by 188% to €32,643K. However, this surge should be viewed in context: it largely results from the provisioning for reorganization accounted in 2024, while revenue growth was more moderate, increasing by 2.8% to €501,106K.
Revenue and Operational Results
The group's revenue stands at €501,106K, up by 2.8% in reported figures (4.1% at constant exchange rates). This growth is based on a 1.8% increase in volumes and a positive price effect of 2.3%, partially offset by an unfavorable exchange rate impact of -1.3%. Concurrently, operating income has leaped by 177.5% to €43,673K, representing 8.7% of revenue. This remarkable progress is largely due to the absence of the €20,035K reorganization provision in France accounted in 2024. EBITDA increased by 11.1% to €71,711K, reflecting an improvement in regular operational performance, independent of non-recurring items.
Gross Margin and Geographic Performance
The gross margin is set at 73.0% of revenue, down by 60 basis points from 73.6% in 2024, reflecting a 5.1% increase in the cost of goods sold. Promotion costs have risen by €6,562K, mainly due to increased advertising investments in France, Asia, and the United States. Geographically, France saw a slight decline of 0.2%, while Europe outside France fell by 2.7%. Conversely, North America saw a significant increase of 14.4%, driven by the rise in winter specialties in the United States, and other regions recorded a 20.4% increase, particularly in Asia.
Financial Health and Future Outlook
Net cash has improved by 10.0% to €70,749K, while cash flow from operations has increased by 6.6% to €59,006K. Net investments have grown by 27.4% to €23,388K, indicating an acceleration of investment expenditures in line with growth objectives. The Board of Directors proposes a dividend distribution of €1.35 per share, to be voted on at the General Meeting on May 21, 2026. For 2026, management indicates that the group's development will depend on the level of seasonal pathologies, the launch of new products, and the global geopolitical situation.
